硼替佐米治疗多发性骨髓瘤的临床研究

发布时间：2018-06-08 18:55

本文选题：多发性骨髓瘤 + 硼替佐米　；参考：《新疆医科大学》2017年硕士论文

【摘要】：目的:研究以硼替佐米联合地塞米松及沙利度胺化疗方案治疗多发性骨髓瘤(MM)的疗效和不良反应。方法:29例患者均采用硼替佐米联合地塞米松及沙利度胺化疗方案:硼替佐米均为1.3mg/m2,在治疗第1、4、8、11天静脉推注给予;地塞米松20-40mg/d,静脉滴注,第1-2,8-9,15-16天(或者4.5-13.5mg/m2,第1-4天、第9-12天、第17-20天);沙利度胺50-200mg口服,每天一次。21天为1个疗程。结果:29例多发性骨髓瘤患者中,初治MM患者19例,复发或难治性MM患者10例,总有效率为89.65%(26/29),CR率为27.58%(8/29)。初治组患者中,总有效率为100%(19/19),其中CR8例,VGPR6例,PR5例。在10例复发难治患者中,总反应率为70%(7/10),其中VGPR3例,PR4例,SD2例,PD1例。主要不良反应包括消化系统不良反应、血液系统不良反应、周围神经病变、感染(以细菌为主,2例患者出现带状疱疹病毒感染)等,经相应的药物对症治疗后可改善,但少数周围神经病变患者出现较重的药物不良反应。结论:硼替佐米化疗方案治疗初治和复发、难治性多发性骨髓瘤患者起效较快,治疗有效率高,不良反应发生率较低。
[Abstract]:Aim: to study the efficacy and side effects of bortezomide combined with dexamethasone and thalidomide in the treatment of multiple myeloma. Methods Twenty nine patients were treated with bortezomil combined with dexamethasone and thalidomide chemotherapy regimen: bortezomib was 1.3 mg / m ~ (2), given intravenously on the 1st day of treatment at 811 d, dexamethasone 20-40 mg / d, intravenously, 1-28-915-16 days (or 4.5-13.5mg / m2, 1-4, 9-12 days), Thalidomide 50-200mg was given orally, once a day. 21 days as a course of treatment. Results among 29 cases of multiple myeloma, 19 cases were newly treated MM and 10 cases were relapsed or refractory MM. The total effective rate was 89.65% 26% 29% and the CR rate was 27.58%. In the first treatment group, the total effective rate was 100% 19 / 19, of which 6 cases were CR8 cases with VGPRs and 5 cases with PR1. In 10 patients with refractory recurrence, the total response rate was 70% 10%, of which 3 cases were VGPR3 cases with PR4 cases with SD2 cases with PD. The main adverse reactions include digestive system adverse reactions, blood system adverse reactions, peripheral neuropathy, infection (mainly bacterial infection of herpes zoster virus) and so on. However, a few patients with peripheral neuropathy had severe adverse drug reactions. Conclusion: bortezomil regimen is effective in the treatment of primary and recurrent multiple myeloma patients, and the effective rate is high, and the incidence of adverse reactions is low.
【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R733.3

【参考文献】